Newly Diagnosed Glioblastoma
Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma.Take PFS as the main evaluation index, the purpose is to evaluate its effectiveness
Glioblastoma
DRUG: Anlotinib Hydrochloride|DRUG: Placebo|RADIATION: Radiation Therapy|DRUG: Temozolomide
Progression Free Survival (PFS) assessed by IRC, PFS was defined as the time from the date of study enrollment to the date of the first of the following events: objective disease progression or death due to any cause., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
The progression free survival (PFS), PFS was defined as the time from the date of study enrollment to the date of the first of the following events: objective disease progression or death due to any cause., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months|Overall survival (OS), OS was defined as the time from the date of study enrollment to the date of death due to any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma.Take PFS as the main evaluation index, the purpose is to evaluate its effectiveness